Huons Partners with Aribio to Develop Treatments for Brain Diseases and Dementia

[Asia Economy Reporter Kim Ji-hee] Huons announced on the 23rd that it has signed a business agreement with new drug development company Aribio for the 'comprehensive improvement of brain diseases and development of dementia treatment drugs.'

This agreement aims for the commercialization and global market entry of Aribio's Alzheimer's treatment drug ‘AR1001’ and other brain disease and dementia target pipelines under development. To this end, both companies plan to maintain a continuous and organic strategic partnership through technology exchange and other means.

Huons has experience obtaining product approval from the U.S. Food and Drug Administration (FDA) and possesses global-level production, manufacturing technology, and facilities. Utilizing these, Huons will be responsible for domestic and international regulatory approval, clinical trial drugs, production, and supply of Aribio's brain disease and dementia pipelines under development.

Aribio is developing the Alzheimer's treatment AR1001 using its proprietary new drug development platform ‘ARIDD.’ Having completed global Phase 2 clinical trials last August, the results will be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference held in Boston, USA, this November. AR1001 has also received FDA approval for Phase 2 clinical trials for the development of a vascular dementia treatment.

Jung Jae-joon, CEO of Aribio, said, “The global Phase 2 clinical trial of AR1001, which is being developed as a dementia treatment, has been completed, and we are at an important point before entering Phase 3. We expect to create synergy in the development of next-generation brain disease and dementia treatments through a strategic alliance with Huons, which has abundant know-how in global regulatory approval and product development.”

Um Ki-an, CEO of Huons, stated, “Through a long-term and comprehensive mutual cooperation relationship with Aribio, we will actively promote not only dementia treatment drugs but also the joint development of additional pipelines.”

In addition to the Alzheimer's treatment AR1001, Aribio holds pipelines including the sepsis treatment candidate AR2001 and the obesity treatment candidate AR3001.